Scaling genetic medicine with tRNA
Posted: 27 September 2024 | Drug Target Review | No comments yet
Tune in to this episode which explores how engineered tRNAs could treat thousands of rare diseases and cancers that share the same mutation.
In this episode, titled ‘Scaling genetic medicine with tRNA‘, we will discuss the unique biology of tRNA and how it can be leveraged to scale the development of genetic medicines.
This conversation features Michelle Werner, CEO of Alltrna and CEO-Partner at Flagship Pioneering, and Caroline Köhrer, Vice President, Discovery Platform at Alltrna.
Key discussion points:
- How tRNA functions in the cell, and the unique attributes that make it a promising candidate for developing genetic medicines
- How addressing stop codons through tRNA-based therapies offers potential solutions
- The challenges that might be encountered in a universal tRNA medicine’s development and implementation
This podcast is in association with Molecular Devices. With its innovative life science technology, Molecular Devices makes scientific breakthroughs possible for academic, pharmaceutical, government and biotech customers. Head to moleculardevices.com to find out more.
About our speakers
Michelle Werner, CEO of Alltrna and CEO-Partner at Flagship Pioneering
Michelle is a seasoned pharmaceutical executive with more than 20 years in the industry spanning both commercial and research & development responsibilities. Prior to Alltrna, she held executive roles in the pharmaceutical industry mainly in the oncology field, including Novartis, AstraZeneca, and Bristol Myers Squibb. Michelle is also a member of the rare disease community, currently serving as a Board appointment for the non-profit organisation Rare Disease Renegades.
Caroline Köhrer, Vice President, Discovery Platform at Alltrna
Dr Kӧhrer leads Alltrna’s Discovery Platform, utilising high-throughput screening infrastructure and machine learning tools, to create tRNA therapeutics to treat thousands of diseases. Prior to Alltrna, Dr Kӧhrer was Director of RNA Science at Moderna, where she developed mRNA-based technology as a new drug modality. Previous to Moderna, she dedicated 20 years at MIT performing research focused on protein synthesis across all kingdoms of life, with an emphasis on tRNA and RNA modifications.
Related topics
Drug Development, Gene Therapy, Oncology, RNAs, Therapeutics
Related conditions
Cancer, Rare diseases
Related organisations
Alltrna
Related people
Caroline Köhrer (Alltrna), Michelle Werner (Alltrna)
